Coronavirus: Commission issues guidance to mitigate clinical trial disruption in the EU

The Commission has published guidance to ensure that clinical trials can continue taking place in the EU during the COVID-19 pandemic. The aim is to mitigate the disruption of clinical research in Europe and therefore the negative effects of the pandemic, without compromising on quality and safety. These recommendations are an important part of the overall strategy in finding treatments and a vaccine to protect citizens against the coronavirus.

With more than 200 coronavirus clinical trials now registered in the EU database (EudraCT), the guidance offers recommendations for simple and flexible measures to respond to the current situation, and to ensure that patients participating in clinical trials across the EU can continue receiving their medicines.

More info and documents click here.